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Background: Pancreatico-jejunostomy strictures (PJS) after pancreatiocoduodenectomy (PD) are
poorly understood.
Methods: Patients treated for PJS were identified from all PDs (n = 357) performed for all indications in
our practice (2002 to 2009). Technical aspects of the original operation, as well as the presentation,
management and outcomes of the resultant stricture were assessed.
Results: Seven patients developed a symptomatic PJS for an incidence of 2%. ‘Soft’ glands and small
ducts (3 mm) were each present in 3/7 of the original anastomoses. Pancreatic fistula occurred in 6/7.
The latency period to stricture presentation averaged 41 months. Diagnosis of PJS was confirmed by
secretin magnetic resonance cholangio-pancreatography (MRCP). Therapeutic endoscopic retrograde
cholangiopancreatography (ERCP) was attempted – each unsuccessfully – in four patients. All patients
required operative correction of their PJS by takedown/revision of the original pancreatico-jejunal anas-
tomoses (PJA) (n = 4)  a modified Puestow (n = 2). One patient’s PJS was completely inaccessible due
to dense adhesions. Another patient’s stricture recurred and was successfully revised with a strictur-
oplasty. At a mean follow-up of 25 months, all are alive, but only 4/7 are pain free.
Conclusion: A symptomatic PJS appears to be independent of original pathological, glandular or
technical features but pancreatic fistulae may contribute. Secretin MRCP is diagnostically useful, whereas
ERCP has been proven to be therapeutically ineffective. Durable resolution of symptoms after surgical
revision is unpredictable.
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Introduction
Pancreaticoduodenectomy (PD) is now commonly performed for
a full array of indications ranging from benign conditions such as
chronic pancreatitis, to pre-malignant lesions like intraductal
papillary mucinous neoplasm (IPMN), to full-fledged malig-
nancy.1 Although in-hospital mortality is now just a fraction of
what it once was, down to under 5% in specialist’s hands,
operative complications are still common. These occur in
approximately 30–50% of patients,2–4 and at different temporal
points in the recovery period. Significant immediate-term adverse
outcomes include clinically relevant pancreatic fistula (CR-POPF;
the most common problem – seen in approximately 15% of
patients),5,6 delayed gastric emptying (DGE), haemorrhage and
various infections.2 Intermediate-term ramifications include both
endocrine and exocrine insufficiency, which occur unpredictably
(around 25% of the time each) and have significant physiological
consequences.7,8
While this morbidity profile has been extensively recognized,
described and studied, less is understood regarding longer-term
sequelae, including structural complications such as anastomotic
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strictures. This problem is particularly germane given the
expanded indications for, and improving survival after, PD.Recent
literature estimates the incidence of bilioenteric anastomotic
strictures to be between 2.5% and 8%.9,10 Yet, little has been pub-
lished regarding the long-term patency and natural history of
pancreatico-jejunal anastomoses (PJA). In a limited review of
PD performed for benign disease only, one study reports a
pancreatico-jejunostomy stricture (PJS) incidence of 5%,10
whereas another, more-extensive investigation claims a 11% rate
in patients exclusively limited to a diagnosis of chronic pancreati-
tis.11 While other surgically-induced strictures (bilioenteric,
entero-enteric) can be addressed through minimally-invasive
endoscopic or radiographic means, management of a PJS is chal-
lenging in that the altered anatomy of the post-PD reconstruction
often precludes successful employment of such techniques.
As so many PJAs (~60%) are constructed in the setting of
malignancy with its attendant short-term lifespan (roughly 2
years), the natural history of a PJA over time is not well under-
stood. Herein, we describe an experience with the presentation,
diagnosis, management and outcomes of post-PD PJS performed
for the full spectrum of pathological indications.
Methods
This series was accrued over an 8-year period (2002–09) at a
multidisciplinary, tertiary-care medical centre with a high-volume
practice in pancreato-biliary surgery. Pancreaticoduodenectomy
was performed by two fellowship-trained pancreatic surgical spe-
cialists (M.P.C. and C.M.V.) for a full range of benign, pre-
malignant and malignant indications. Two patients’ index PD
operations were performed elsewhere by other surgeons anteced-
ent to 2002. Pancratico-jejunostomy (PJ) was always performed
(including the two operations performed by others) as the form of
enteric reconstruction in all patients with the exception of four
pancreatico-gastrostomies (PG) which were excluded from analy-
sis. PJA in the setting of central pancreatectomy was also excluded
because of this limited cohort (<10 patients).
The PJA was always performed in an end-to-side, duct-to-
mucosa fashion in one (31%) or two (69%) layers. The inner
ductal anastomosis was constructed with interrupted 5-0, 6-0 or
7-0 absorbable sutures placed in a radial fashion, whereas the
outer layer approximated the pancreatic capsule to the serosa of
the jejunum with interrupted 3-0 silk sutures. A PJ anastomotic
stent (usually a short and internalized, but sometimes a long and
externalized, 5-F paediatric feeding tube) was infrequently placed
in situations perceived at high risk for the development of a
pancreatic fistula. Prophylactic octreotide was administered in
selected cases with recognized risk factors,12,13 and fibrin glue was
rarely applied (fewer than five patients).
Specific patient characteristics and results were accrued from an
Institutional Review Board (IRB)-approved prospective database.
Patients who developed a PJS that required revision were identi-
fied from all PDs performed in that time period. Previously devel-
oped risk factors for CR-POPF were analysed with the supposition
that fistula development may eventually lead to stricture forma-
tion.6,11 Data were not sought on those asymptomatic patients
with sub-clinical (e.g. ductal dilation, glandular atrophy) or clini-
cal (diabetes) evidence of PJ stenosis. Technical aspects of the
original operation, and the subsequent presentation and manage-
ment of the resultant stricture, were assessed.
Investigation of symptomatic abdominal pain included bio-
chemical analysis for evidence of pancreatitis, as well axial
imaging, including both computed tomography and magnetic
resonance cholangio-pancreatography (MRCP) with secretin
administration. Operative interventions were undertaken in those
patients with debilitating abdominal pain and evidence of a
stenotic anastomosis from secretin MRCP analysis who failed
less-invasive treatment modalities (enzyme supplementation,
narcotics and endoscopic interventions). Short- and long-term
outcomes of revision operations were analysed. Post-repair
follow-up was performed via longitudinal visits in the surgeon’s
clinic with emphasis on recurrence of abdominal pain (and its
nature), as well as the new-onset or acceleration of exocrine insuf-
ficiency or diabetes. Exocrine insufficiency was measured by the
presence of steatorhea, persistent weight-loss or the need for addi-
tional enzymatic supplementation. Faecal elastase measurement
has not been employed.
Diagnosis of PJS was secured in all cases through the use of
MRCP with secretin in the setting of clinically-relevant pain. MR
examinations were performed in either a 1.5T (GE Twin or HDX,
GE Healthcare; Vision, Symphony, or Espree, Siemens) or 3T (GE
HDX) clinical scanner, using a phased-array coil, with the patients
in the supine position. The secretin MRCP (sMRCP) protocol
includes standard T1-weighted and T2-weighted images. A base-
line thick-slab MRCP image was obtained followed by the intra-
venous injection over 1 min of secretin at a weight-dependent
dose (0.2 mcg/kg). MRCP thick-slab images are then obtained
every 30 s for 10 min. Finally, three-dimensional dynamic
gradient-echo images are acquired before and after the intrave-
nous administration of a bolus of gadolinium (0.1 mmol/kg)
during the arterial, portal and delayed venous phase.
MR examinations were interpreted by one of six MRI
fellowship-trained radiologists in direct conjunction with the
referring surgeon. The imaging findings for both the routine
MRCP and the Secretin-enhanced MRCP examinations were
assessed. Anatomic variants (i.e. pancreas divisum, dominant
dorsal duct and aberrant ductal communications) and ductal
pathology including filling defects, stenosis or obstruction, on
standard and secretin-enhanced MRCP images was recorded.
Similarly, non-ductal pancreatic pathology including the presence
of solid/cystic masses, atrophy or extrapancreatic disease was dis-
cerned. Symptoms associated with secretin administration were
also elicited. PJS was defined by the presence of a fixed filling
defect at the anastomotic site, along with post-obstructive ductal
dilation, side-branch enhancement and/or decreased functional
excretion into the jejunal drainage limb.
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Results
Patients
Original operation
Over the 8-year study period, 357 PDs were performed in this
specialty practice for the following diagnoses: pancreatic adeno-
carcinoma (n = 146; 41%), other periampullary malignancies (n =
64; 18%), chronic pancreatitis (n = 50; 14%), cystic lesions (n = 43;
12%), benign lesions (n = 29; 8%), neuroendocrine tumours (n =
11; 3%), metastatic lesions (n = 7; 2%) and other indications (n =
7; 2%). Seven patients, with a wide variety of original diagnoses,
eventually presented with a PJS, which manifest with symptom-
atic abdominal pain, for an overall rate of 2% (Table 1). Excluding
the two patients originally resected by other surgeons, the inci-
dence of symptomatic stricture formation in our practice was
1.4% (5/357). Among the seven patients who went on to develop
PJS, four were noted at the time of original surgery to have ‘firm’
glands, while three were noted to have ‘soft’ glands. Additionally,
the pancreatic duct was small (3 mm) in just 3/7 patients. The
original PJA was constructed over a short, internalized stent in
16% of the overall series and in 2/7 of patients with an ultimate
PJS. A CR-POPF occurred in 6/7 of the original operations.
Pancreaticojejunostomy stricture
The latency period from original resection to clinical presentation
of PJS was a median time of 18 months with a single 10-year
outlier (range: 8–120 months). All seven patients had abdominal
pain typical of obstructive pancreatopathy, with either episodic or
post-prandial epigastric abdominal pain. Five patients had bio-
chemical evidence of pancreatitis (Table 1). Narcotic use was
common (5/7). Strictures were definitively diagnosed using secre-
tin MRCP in all patients, and minimally invasive therapeutic
intervention via endoscopic retrograde cholangiopancreatogra-
phy (ERCP) was attempted in four patients. However, each of
these were unsuccessful for one of two reasons: (i) the PJA was
inaccessible because of the altered anatomy of the pancreaticobil-
iary limb used for PD reconstruction, or (ii) if successfully iden-
tified, the PJS was unable to be cannulated owing to either the
tight/complete degree of stenosis or there were technical chal-
lenges of ERCP with such unorthodox positioning.
All patients required operative intervention with takedown/
revision of the original PJA (n = 4), and/or a ‘modified Puestow’
procedure (n = 2). Revised anastomoses were performed in one or
two layers, after a short segment (~1 cm) of remnant pancreas was
resected – usually revealing a somewhat dilated pancreatic duct.
For the ‘modified Puestow’ patients, the new anastomosis was
extended longitudinally along the anterior pancreatic duct for a
centimetre or two to assure wide patency. There was sufficient
redundancy of the pancreaticobiliary jejunal limb such that it
could be reused for the new anastomosis without requiring a
newly-fashioned Roux-en-Y conduit. An anastomotic stent
was used in four instances. Median estimated blood loss for
these revisions was 175 mL. There were no mortalities, two Ta
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post-operative complications (UTI, prolonged ileus) and a
median LOS of 8 days (range: 5–14).
In one patient (no. 6, Table 1), the pancreas and PJA were
completely inaccessible because of dense adhesions (17 months
later). An intra-operative ERCP was attempted via the pancreati-
cobiliary drainage limb, but was again unsuccessful in identifying
the stenosed PJ orifice. The proposed anastomotic revision was
abandoned after a transverse colectomy was required for colonic
ischaemia induced by the dissection and the post-operative recov-
ery was uneventful. The patient continues to suffer from episodic
abdominal pain.
Follow up
At a median follow-up time of 18 months (range: 12 to 57
months), all patients are alive, but only 4 out of 7 patients are
completely pain free. None have evidence of declining exocrine
(use of pancreatic enzyme supplementation and steattorhea) or
endocrine (accelerated diabetes) function. However, two of these
symptomatic patients have demonstrated overt biochemical pan-
creatitis. One of these two patients (no. 7, Table 1) had a PJS recur
a second time 18 months after a primary repair, and was success-
fully managed with a stricturoplasty achieved through the ante-
rior wall of the jejunal limb. An externalized stent was employed
and interrogated radiographically 6 weeks later – showing no
evidence of any stenosis or diminished flow across the anastomo-
sis. The patient is now symptom free.
Discussion
Recovery after PD can be viewed in a continuum of three tempo-
ral phases: immediate, intermediate and long term. There is a vast
body of literature on peri-operative mortality14,15 as well as short-
term complications3,4,16 for PD. Foremost among these is the most
feared and difficult to manage complication – pancreatic anasto-
motic failure.17 Other problems such as permanent endocrine and
exocrine dysfunction usually manifest within the first month of
recovery. Conversely, little has been described of the longer-term
complications of PD, and specifically those relating to the biliary
and pancreatic anastomoses. This is partly because of the fact that
many patients with malignant diagnoses do not live long enough
after PD for there to be adequate numbers to study. Furthermore,
many patients may live remotely from their regional centres of
specialization, and others can be lost to follow-up from their
original surgeons.
However, with the increased safety and better outcomes of PD,
the operation has found a wider range of applications beyond
malignancies – including premalignant conditions such as IPMN,
neuroendocrine tumors and gastrointestinal stromal tumours, as
well as benign maladies such as chronic pancreatitis. As a result,
there are more patients to study and follow with improved life
spans, and thus the longer-term morbidity of PD is becoming
evident. House et al. reported on biliary strictures in their large
series of PD for all indications, whereas Reid-Lombardo et al.
published similarly on biliary and pancreatic strictures in those
who underwent PD for benign disease exclusively.9,10 The latter
series found four PJS for a rate of 3.3%, two of which were recti-
fied surgically. While there have been other descriptions of PJS in
the literature, they have been largely limited to single-case reports
describing therapeutic techniques.18–20 Most recently, Morgan
et al. reported of a large cohort of pancreatic head resections
performed for pancreatitis with a significant PJS rate (11%) over
a 56-month follow-up.11
This current series, evaluating PD performed for a variety of
indications – both benign andmalignant – expands on this knowl-
edge base.We believe it is necessary to consider this problem in the
differential diagnosis for all patients who present with chronic
abdominal pain after a partial pancreatectomy with PJ reconstruc-
tion. The rate of PJS resulting in symptomatic pain in this series is
low, under 2%, with a mean time to presentation with the compli-
cation of 41 months. This number is certainly skewed by one
patient, but even with the exclusion of this data point, the mean is
still close to 26 months. Occurrence of PJS appears to be indepen-
dent of original pathological, glandular and technical features – but
perhaps is most affected by the development of clinically-relevant
post-operative pancreatic fistulae which induce aggressive local
inflammation and an accentuated repair response marked by
development of fibrosis. Morgan’s group has suggested that an
original diagnosis of chronic pancreatitis may similarly contribute
to anastomotic stenosis. That analysis, where PJA revisions were
also performed for intractable pain, came to similar conclusions in
that specific population aswe havewith broader indications for the
original pancreatic resection presented herein. That is, long-term
pain relief following anastomotic revision is dubious.11 Our rate of
PJS in patients suffering from chronic pancreatitis was not as
impressive (4%, 2/49). However, another patient (no. 7, Table 1)
suffered chronic pancreatitis of his pancreatic remnant as a result of
his first PJS, and this required a revision via a stricturoplasty,which
has provided definitive pain relief.
The primary limitation of this single institutional experience is
that this series did not address the scenario of sub-clinical evi-
dence of anastomotic stenosis, which probably occurs more
frequently than we are aware. This could be completely asymp-
tomatic, or might manifest subtly as new-onset or progressive
diabetes or exocrine insufficiency. It is not our policy to screen for
such findings with regular imaging after all PDs to interrogate the
characteristics of either the pancreatic duct or the glandular archi-
tecture. However, it is not uncommon to see evidence of mild
ductal dilation or even radiographical features of chronic pancre-
atitis in those patients who have been serially followed with
imaging – perhaps for surveillance for recurrence of malignancy.
In this series, patients who developed complications from a PJS
were readily identified because of the predominant symptom
of abdominal pain, and/or the development of biochemical
pancreatitis.
While, similar to the Morgan series, all patients treated in this
series had overt pain as an indication of their stenosis, it could be
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argued that an operative approach could also be valuable for those
patients who manifest with these other, less obvious and debili-
tating, symptoms. Generally, operative consideration has thus far
been tempered by the fact that these scenarios have less invasive,
medical management strategies available. However, it is conceiv-
able that earlier surgical intervention for such strictures may ame-
liorate declining pancreatic function. Secretin MRCP proved a
useful tool for diagnosis as it allows for a ‘functional’ test of the
remnant pancreas, and it is more discriminating for ductal steno-
sis than is traditional static MRCP.21 Furthermore, ongoing
follow-up of all patients who had an original PD is limited and
sometimes haphazard given the large territory our regional refer-
ral centre serves. We typically follow these patients with clinical
visits through the first year and address complications on
an as-needed basis thereafter. Therefore, the true incidence
of anastomotic stricture formation in this series may be
underappreciated.
There are reports of using balloon dilatation with or without
stenting to alleviate stricture-related symptoms.10 Of the 122
patients in the series from the Mayo Clinic, four PJS were
reported. Two patients were managed operatively with revision of
the PJA,whereas the remaining two were managed endoscopically,
and all four patients were symptom free at follow-up. However,
these minimally-invasive measures proved unsuccessful in our
patients. In fact, all patients went on to require operative (or
attempted operative) revision of their PJAs. In one patient (no. 6,
Table 1), even intra-operative ERCP access directly into the enteric
limb was futile after the pancreas was inaccessible from dense
adhesions.
Operative revisions of these strictures can be technically
demanding and require flexibility on the surgeons part. The first
challenge is navigating to the pancreas through what can be a field
of dense adhesions and scar tissue, particularly when a pancreatic
fistula originally occurred. In one patient, we were unsuccessful at
even safely identifying the pancreas. In fact, the blood supply to
the transverse colon was compromised and required a partial
colectomy. If the PJA is in fact identified, complete dissection of
the strictured limb-pancreas complex off the underlying porto-
splenic venous confluence may be possible. In that situation, a
complete revision may be undertaken by resecting back on the
pancreas over a centimetre from the stricture. This usually iden-
tifies a moderately dilated pancreatic duct suitable for another
end-to-side duct-to-mucosa apposition. In other cases, the degree
of ductal dilation is minimal and the reconstruction to another
small duct may be unsatisfying. In such a circumstance, a ‘modi-
fied Puestow’ might be possible by longitudinally opening the
duct on its anterior surface for a few centimetres. Usually there is
enough redundancy in the end of the jejunal limb to appose it as
a hood over the pancreatic duct trough. However, in some
patients, pancreatitis induced by the obstructing stricture may
make the strictured anastomotic complex ‘frozen’. If this is
encountered, a trans-jejunal stricturoplasty can be entertained.
Finally, if a markedly dilated obstructed duct (>6 mm) is the
circumstance, longitudinal drainage procedures (a traditional
Puestow or a side-to-side pancreaticogastrostomy) are options.22
PG offers an alternative method of reconstruction after pancre-
aticoduodenectomy and is favoured by some surgeons over pan-
creaticojejunostomy, especially for soft glands. Putatively, this may
be less prone to long-term stricture formation – particularly if the
remnant pancreas is introduced into the posterior stomach wall
for a distance of a few centimetres without a direct apposition of
the pancreatic duct to the gastric mucosa (as described by Bassi
et al.23). We have a limited and unfavourable experience with this
technique, with three out of four patients developing symptom-
atic post-operative ductal stenosis. In each circumstance, the pan-
creatic tissue and duct was obscured by overgrowth of the gastric
mucosa. Literature about rates of this complication after PG is
lacking, however, there are papers describing both endoscopic24
and surgical22,25 solutions to this dilemma. Another series of 61
PGs indicates that stricture is a significant factor in the develop-
ment of post-operative pancreatic exocrine insufficiency.26
Finally, a technically satisfying revision operation does not
guarantee long-term symptom relief. Just over half of our patients
are pain free after a mean follow-up of 2 years. This unpredictable
outcome may reflect inaccurate diagnosis of the source of the
original abdominal pain. Pancreatitic pain could be attributed to
stricturing of the pancreatic duct remote from the anastomotic
site. However, this scenario was not recognized on any of our
patients on either their pre- or post-operative MRCP imaging.
Causes of abdominal pain beyond clinically evident pancreatitis
should be explored pre-operatively. Patients with recurrent pain
after a stricture revision should be worked-up de novo for another
PJS, as we had one patient who indeed benefited from another
operative endeavour. However, once a stricture originally occurs,
obstructive pancreatitis is induced in what was most often normal
pancreas at the index procedure. As pointed out by Morgan, the
contribution of such fibrotic pancreatitic changes to chronic
abdominal pain remains elusive.11 While the stricture may con-
tribute to episodic pancreatitis events, chronic, enduring pain is
most likely from the resultant fibrosis which may not manifest
biochemically.
Conclusions
Occurrence of PJS is rare and appears to be independent of origi-
nal pathological, glandular or technical features; however, pancre-
atic fistula likely predispose to PJS by inducing an inflammatory
reaction with aggressive scar formation. Secretin MRCP provides
a useful, non-invasive tool to identify these strictures, whereas
ERCP has proven therapeutically ineffective. Operative solutions
(PJA revision, remnant resection and ductal obliteration) are
often required, and require technical flexibility.As the incidence of
this complication is still small, it is difficult to draw absolute
conclusions, although it appears that durable resolution of symp-
toms after surgical revision is unpredictable. The number of
longer-term survivors after PD is likely to grow in the next several
486 HPB
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years, providing further opportunity to study long-term
complications.
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